1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Epilepsy	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	disorder	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	central	_	_	JJ	_	_	_	_	_
8	nervous	_	_	JJ	_	_	_	_	_
9	system	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	CNS	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	characterized	_	_	VBN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	increase	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	number	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	electrical	_	_	JJ	_	_	_	_	_
24	impulses	_	_	NNS	_	_	_	_	_
25	that	_	_	WDT	_	_	_	_	_
26	occurs	_	_	VBZ	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	one	_	_	CD	_	_	_	_	_
29	focal	_	_	JJ	_	_	_	_	_
30	locus	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	brain	_	_	NN	_	_	_	_	_
34	and/or	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	entire	_	_	JJ	_	_	_	_	_
37	brain	_	_	NN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	resulting	_	_	VBG	_	_	_	_	_
40	in	_	_	IN	_	_	_	_	_
41	partial	_	_	JJ	_	_	_	_	_
42	or	_	_	CC	_	_	_	_	_
43	generalized	_	_	VBN	_	_	_	_	_
44	seizures	_	_	NNS	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	administration	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	antiepileptic	_	_	JJ	_	_	_	_	_
5	drugs	_	_	NNS	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	mostly	_	_	RB	_	_	_	_	_
8	done	_	_	VBN	_	_	_	_	_
9	via	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	oral	_	_	JJ	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	intravenous	_	_	JJ	_	_	_	_	_
14	routes	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Drug	_	_	NN	_	_	_	_	_
2	resistance	_	_	NN	_	_	_	_	_
3	at	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	late	_	_	JJ	_	_	_	_	_
6	stage	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	therapy	_	_	NN	_	_	_	_	_
9	develops	_	_	VBZ	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	about	_	_	RB	_	_	_	_	_
12	40	_	_	CD	_	_	_	_	_
13	%	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	patients	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Drug	_	_	NN	_	_	_	_	_
2	resistance	_	_	NN	_	_	_	_	_
3	leads	_	_	VBZ	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	uncontrolled	_	_	JJ	_	_	_	_	_
6	seizures	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	higher	_	_	JJR	_	_	_	_	_
10	risk	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	brain	_	_	NN	_	_	_	_	_
13	damage	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	increased	_	_	VBN	_	_	_	_	_
17	mortality	_	_	NN	_	_	_	_	_
18	rates	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Patients	_	_	NNS	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	epilepsy	_	_	NN	_	_	_	_	_
4	suffer	_	_	VBP	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	emotional	_	_	JJ	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	behavioral	_	_	JJ	_	_	_	_	_
9	changes	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	seizures	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	convulsions	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	muscular	_	_	JJ	_	_	_	_	_
16	spasms	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	depression	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	some	_	_	DT	_	_	_	_	_
23	cases	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	unconsciousness	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Drugs	_	_	NNS	_	_	_	_	_
2	used	_	_	VBN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	treatment	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	epilepsy	_	_	NN	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	poor	_	_	JJ	_	_	_	_	_
10	bioavailability	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	eventually	_	_	RB	_	_	_	_	_
13	become	_	_	VBN	_	_	_	_	_
14	ineffective	_	_	JJ	_	_	_	_	_
15	over	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	course	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	treatment	_	_	NN	_	_	_	_	_
20	due	_	_	JJ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	drug	_	_	NN	_	_	_	_	_
23	resistance	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Epilepsy	_	_	NN	_	_	_	_	_
2	treatment	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	often	_	_	RB	_	_	_	_	_
5	complicated	_	_	JJ	_	_	_	_	_
6	due	_	_	JJ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	poor	_	_	JJ	_	_	_	_	_
10	release	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	drug	_	_	NN	_	_	_	_	_
14	through	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	adjunctive	_	_	JJ	_	_	_	_	_
17	blood	_	_	NN	_	_	_	_	_
18	–	_	_	:	_	_	_	_	_
19	brain	_	_	NN	_	_	_	_	_
20	barrier	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	which	_	_	WDT	_	_	_	_	_
23	may	_	_	MD	_	_	_	_	_
24	be	_	_	VB	_	_	_	_	_
25	overcome	_	_	VBN	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	preparation	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	drug	_	_	NN	_	_	_	_	_
32	as	_	_	IN	_	_	_	_	_
33	solid	_	_	JJ	_	_	_	_	_
34	lipid	_	_	NN	_	_	_	_	_
35	nanoparticles	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	ideal	_	_	JJ	_	_	_	_	_
3	delivery	_	_	NN	_	_	_	_	_
4	systems	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	antiepileptic	_	_	JJ	_	_	_	_	_
7	drugs	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	ones	_	_	NNS	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	provide	_	_	VBP	_	_	_	_	_
13	localized	_	_	VBN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	controlled	_	_	VBN	_	_	_	_	_
16	drug	_	_	NN	_	_	_	_	_
17	release	_	_	NN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	targeted	_	_	VBN	_	_	_	_	_
20	sites	_	_	NNS	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	brain	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	which	_	_	WDT	_	_	_	_	_
26	helps	_	_	VBZ	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	reduce	_	_	VB	_	_	_	_	_
29	drug-associated	_	_	JJ	_	_	_	_	_
30	toxicities	_	_	NNS	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	enhances	_	_	VBZ	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	efficacy	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	drug	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Carbamazepine	_	_	NNP	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	CBZ	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	antiepileptic	_	_	JJ	_	_	_	_	_
8	drug	_	_	NN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	narrow	_	_	JJ	_	_	_	_	_
12	therapeutic	_	_	JJ	_	_	_	_	_
13	index	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	it	_	_	PRP	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	poorly	_	_	RB	_	_	_	_	_
19	absorbed	_	_	VBN	_	_	_	_	_
20	when	_	_	WRB	_	_	_	_	_
21	taken	_	_	VBN	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	oral	_	_	JJ	_	_	_	_	_
25	route	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Its	_	_	PRP$	_	_	_	_	_
2	oral	_	_	JJ	_	_	_	_	_
3	bioavailability	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	75	_	_	CD	_	_	_	_	_
6	%	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	its	_	_	PRP$	_	_	_	_	_
10	maximum	_	_	JJ	_	_	_	_	_
11	achieved	_	_	VBN	_	_	_	_	_
12	plasma	_	_	NN	_	_	_	_	_
13	concentration	_	_	NN	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	about	_	_	RB	_	_	_	_	_
16	4	_	_	CD	_	_	_	_	_
17	–	_	_	TO	_	_	_	_	_
18	8	_	_	CD	_	_	_	_	_
19	h	_	_	NNS	_	_	_	_	_
20	after	_	_	IN	_	_	_	_	_
21	administration	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Carbamazepine	_	_	NNP	_	_	_	_	_
2	acts	_	_	VBZ	_	_	_	_	_
3	through	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	inactivation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	sodium	_	_	NN	_	_	_	_	_
8	channels	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	making	_	_	VBG	_	_	_	_	_
11	brain	_	_	NN	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	less	_	_	RBR	_	_	_	_	_
14	excitable	_	_	JJ	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Solid	_	_	JJ	_	_	_	_	_
2	lipid	_	_	NN	_	_	_	_	_
3	nanoparticles	_	_	NNS	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	SLNs	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	considered	_	_	VBN	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	alternative	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	colloidal	_	_	JJ	_	_	_	_	_
13	systems	_	_	NNS	_	_	_	_	_
14	like	_	_	IN	_	_	_	_	_
15	liposome	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	noisome	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	polymeric	_	_	JJ	_	_	_	_	_
20	nanoparticles	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	SLNs	_	_	NNS	_	_	_	_	_
2	consist	_	_	VBP	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	solid	_	_	JJ	_	_	_	_	_
5	lipids	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	which	_	_	WDT	_	_	_	_	_
8	act	_	_	VBP	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	stabilizer	_	_	NN	_	_	_	_	_
12	when	_	_	WRB	_	_	_	_	_
13	dispersed	_	_	VBN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	water	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	presence	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	surfactant	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	SLN	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	characterized	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	its	_	_	PRP$	_	_	_	_	_
6	small	_	_	JJ	_	_	_	_	_
7	size	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	nano	_	_	NN	_	_	_	_	_
10	range	_	_	NN	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	large	_	_	JJ	_	_	_	_	_
14	surface	_	_	NN	_	_	_	_	_
15	area	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	high	_	_	JJ	_	_	_	_	_
19	drug	_	_	NN	_	_	_	_	_
20	loading	_	_	NN	_	_	_	_	_
21	capacity	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	it	_	_	PRP	_	_	_	_	_
5	improves	_	_	VBZ	_	_	_	_	_
6	drug	_	_	NN	_	_	_	_	_
7	stability	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	ability	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	improve	_	_	VB	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	oral	_	_	JJ	_	_	_	_	_
16	bioavailability	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	poorly	_	_	RB	_	_	_	_	_
19	water-soluble	_	_	JJ	_	_	_	_	_
20	drugs	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Gangurde	_	_	NNP	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	Kumar	_	_	NNP	_	_	_	_	_
4	prepared	_	_	VBD	_	_	_	_	_
5	lamotrigine	_	_	NN	_	_	_	_	_
6	solid	_	_	JJ	_	_	_	_	_
7	lipid	_	_	NN	_	_	_	_	_
8	nanoparticles	_	_	NNS	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	high	_	_	JJ	_	_	_	_	_
12	efficacy	_	_	NN	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	treatment	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	epilepsy	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_
18	Nair	_	_	NNP	_	_	_	_	_
19	et	_	_	FW	_	_	_	_	_
20	al.	_	_	FW	_	_	_	_	_


1	prepared	_	_	VBN	_	_	_	_	_
2	carbamazepine	_	_	NN	_	_	_	_	_
3	solid	_	_	JJ	_	_	_	_	_
4	lipid	_	_	NN	_	_	_	_	_
5	nanoparticles	_	_	NNS	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	improve	_	_	VB	_	_	_	_	_
8	its	_	_	PRP$	_	_	_	_	_
9	therapeutic	_	_	JJ	_	_	_	_	_
10	effect	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_
12	Kumar	_	_	NNP	_	_	_	_	_
13	et	_	_	FW	_	_	_	_	_
14	al.	_	_	FW	_	_	_	_	_


1	prepared	_	_	VBN	_	_	_	_	_
2	solid	_	_	JJ	_	_	_	_	_
3	lipid	_	_	NN	_	_	_	_	_
4	nanoparticles	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	methylthioadenosine	_	_	NN	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	management	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	neurological	_	_	JJ	_	_	_	_	_
12	conditions	_	_	NNS	_	_	_	_	_
13	via	_	_	IN	_	_	_	_	_
14	oral	_	_	JJ	_	_	_	_	_
15	delivery	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	objective	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	current	_	_	JJ	_	_	_	_	_
6	study	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	prepare	_	_	VB	_	_	_	_	_
10	carbamazepine	_	_	NN	_	_	_	_	_
11	solid	_	_	JJ	_	_	_	_	_
12	lipid	_	_	NN	_	_	_	_	_
13	nanoparticles	_	_	NNS	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	CBZ-SLNs	_	_	NNP	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	novel	_	_	JJ	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	alternative	_	_	JJ	_	_	_	_	_
22	method	_	_	NN	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	other	_	_	JJ	_	_	_	_	_
25	colloidal	_	_	JJ	_	_	_	_	_
26	dispersion	_	_	NN	_	_	_	_	_
27	carriers	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	aimed	_	_	VBD	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	prepare	_	_	VB	_	_	_	_	_
6	CBZ-SLNs	_	_	NNP	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	high	_	_	JJ	_	_	_	_	_
9	entrapment	_	_	NN	_	_	_	_	_
10	efficiency	_	_	NN	_	_	_	_	_
11	%	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	small	_	_	JJ	_	_	_	_	_
14	particle	_	_	NN	_	_	_	_	_
15	size	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	high	_	_	JJ	_	_	_	_	_
19	anticonvulsant	_	_	JJ	_	_	_	_	_
20	activity	_	_	NN	_	_	_	_	_
21	compared	_	_	VBN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	free	_	_	JJ	_	_	_	_	_
24	CBZ	_	_	NNP	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_

